CalciMedica, Inc.
$5.12
-1.9%CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -2.9).
Valuation inputs: P/E -2.9, earnings yield N/A, momentum -1.9%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -95.1%, ROIC -1.5%).
Profitability stack: net margin 0.0%, ROE -95.1%, ROIC -1.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +27.2%, momentum -1.9%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
CalciMedica, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
CalciMedica, Inc. Fair Value Envelope
No Revenue Data
CALC has not reported any revenue values in the available annual periods.
CalciMedica, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
CALC has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
CALC has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
CALC has not reported any net profit margin values in the available annual periods.
CalciMedica, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
CalciMedica, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
CalciMedica, Inc. Street Expectations Map
Wall Street analysts project that CALC stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 266.00, with estimates ranging from a low of 14.00 to a high of 392.00.
The consensus 1-year price target stands at 266.00, with estimates ranging from a low of 14.00 to a high of 392.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
CalciMedica, Inc. Insider Positioning
During the last 12 months, insiders have purchased $249K and sold $4K worth of CALC shares, resulting in $246K of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
13.2K
39.76K
0
0.00
+40K
+$40K
9-12 Months
85.2K
209.48K
1.0K
3.65K
+206K
+$206K
Top Buyers
Roberts Eric W
Director, 10 Percent Owner, Officer: Chief Business Officer
$175K
Hebbar Sudarshan
Officer: Chief Medical Officer
$43K
Wilson Robert N
Director
$13K
Leheny A. Rachel
Director, 10 Percent Owner, Officer: Chief Executive Officer
$10K
Stauderman Kenneth A.
Officer: Chief Scientific Officer
$6K
Top Sellers
Stauderman Kenneth A.
Officer: Chief Scientific Officer
$4K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $246K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Insider Participation
5 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
No Dividend Yield Data
CALC has not reported any dividend yield values in the available annual periods.
calc Dividend History
Learning Layer
Related Guides
Build conviction on CALC by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.